ROCK2 and Hepatic fibrosis: These results indicate that GV101-mediated selective inhibition of ROCK2 can inhibit both inflammatory and metabolic pathways specifically in monocytes, circulating innate immune cells, and reveal a novel mechanism by which GV101 can attenuate inflammation-related liver fibrosis.